UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1448-2
Program Prior Authorization/Notification
Medication Winrevair ™ (sotatercept-csrk)
P&T Approval Date 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Winrevair (sotatercept-csrk) is an activin signaling inhibitor indicated for the treatment of adults
with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity,
improve WHO functional class (FC) and reduce the risk of clinical worsening events.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Winrevair will be approved based on the following criterion:
a. Diagnosis of pulmonary arterial hypertension
Authorization will be issued for 12 months.
B. Reauthorization
1. Winrevair will be approved based on the following criterion:
a. Documentation of positive clinical response to Winrevair therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limitations may be in place.
4. References:
1. Winrevair [package insert]. Rahway, NJ: Merck & Co., Inc; March 2024
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification – Winrevair ™ (sotatercept-csrk)
Change Control
6/2024 New program
6/2025 Annual review. No changes to coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
2